
A treatment that targets immune cells’ primary adenosine receptor.
At iTeos we are pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics.
EOS-448 is a human immunoglobulin antibody that we are developing to inhibit the immunosuppressive activity of TIGIT, a cell receptor expressed on multiple immune cells, including CD8+ T cells, natural killer (NK) cells, and T regulatory cells (Tregs).
Our differentiated development approach is driven by biologic rationale and clinical need utilizing our IO candidates in intra-portfolio combinations and with programs of external collaborators.
Latest press releases
iTeos Reports Fourth Quarter and Full Year 2022 Financial Results and Provide…
– 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and…
iTeos to Present at Cowen 43rd Annual Health Care Conference
WATERTOWN, Mass. and GOSSELIES, Belgium, Feb. 28, 2023 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company…